185 related articles for article (PubMed ID: 27171671)
21. Data Mining as a Guide for the Construction of Cross-Linked Nanoparticles with Low Immunotoxicity via Control of Polymer Chemistry and Supramolecular Assembly.
Elsabahy M; Wooley KL
Acc Chem Res; 2015 Jun; 48(6):1620-30. PubMed ID: 26011318
[TBL] [Abstract][Full Text] [Related]
22. Main trends of immune effects triggered by nanomedicines in preclinical studies.
Halamoda-Kenzaoui B; Bremer-Hoffmann S
Int J Nanomedicine; 2018; 13():5419-5431. PubMed ID: 30271138
[TBL] [Abstract][Full Text] [Related]
23. Immunophenotyping: Analytical approaches and role in preclinical development of nanomedicines.
Newton HS; Dobrovolskaia MA
Adv Drug Deliv Rev; 2022 Jun; 185():114281. PubMed ID: 35405297
[TBL] [Abstract][Full Text] [Related]
24. From immunotoxicity to nanotherapy: the effects of nanomaterials on the immune system.
Smith MJ; Brown JM; Zamboni WC; Walker NJ
Toxicol Sci; 2014 Apr; 138(2):249-55. PubMed ID: 24431216
[TBL] [Abstract][Full Text] [Related]
25. Toxicology of nanoparticles.
Durnev AD
Bull Exp Biol Med; 2008 Jan; 145(1):72-4. PubMed ID: 19024007
[TBL] [Abstract][Full Text] [Related]
26. Form Follows Function: Nanoparticle Shape and Its Implications for Nanomedicine.
Kinnear C; Moore TL; Rodriguez-Lorenzo L; Rothen-Rutishauser B; Petri-Fink A
Chem Rev; 2017 Sep; 117(17):11476-11521. PubMed ID: 28862437
[TBL] [Abstract][Full Text] [Related]
27. Nanoparticle surface characterization and clustering through concentration-dependent surface adsorption modeling.
Chen R; Zhang Y; Sahneh FD; Scoglio CM; Wohlleben W; Haase A; Monteiro-Riviere NA; Riviere JE
ACS Nano; 2014 Sep; 8(9):9446-56. PubMed ID: 25133703
[TBL] [Abstract][Full Text] [Related]
28. Nanomedicine drug development: a scientific symposium entitled "Charting a roadmap to commercialization".
Finch G; Havel H; Analoui M; Barton RW; Diwan AR; Hennessy M; Reddy V; Sadrieh N; Tamarkin L; Wolfgang M; Yerxa B; Zolnik B; Liu M
AAPS J; 2014 Jul; 16(4):698-704. PubMed ID: 24821054
[TBL] [Abstract][Full Text] [Related]
29. Sizing up the Next Generation of Nanomedicines.
Clogston JD; Hackley VA; Prina-Mello A; Puri S; Sonzini S; Soo PL
Pharm Res; 2019 Dec; 37(1):6. PubMed ID: 31828540
[TBL] [Abstract][Full Text] [Related]
30. Nanomedicine of anastrozole for breast cancer: Physicochemical evaluation, in vitro cytotoxicity on BT-549 and MCF-7 cell lines and preclinical study on rat model.
Shavi GV; Nayak UY; Maliyakkal N; Deshpande PB; Raghavendra R; Kumar AR; Reddya MS; Udupa N; Shrawan B
Life Sci; 2015 Nov; 141():143-55. PubMed ID: 26423561
[TBL] [Abstract][Full Text] [Related]
31. Safety of Nanoparticles in Medicine.
Wolfram J; Zhu M; Yang Y; Shen J; Gentile E; Paolino D; Fresta M; Nie G; Chen C; Shen H; Ferrari M; Zhao Y
Curr Drug Targets; 2015; 16(14):1671-81. PubMed ID: 26601723
[TBL] [Abstract][Full Text] [Related]
32. Inorganic hollow nanoparticles and nanotubes in nanomedicine Part 1. Drug/gene delivery applications.
Son SJ; Bai X; Lee SB
Drug Discov Today; 2007 Aug; 12(15-16):650-6. PubMed ID: 17706547
[TBL] [Abstract][Full Text] [Related]
33. Shape matters when engineering mesoporous silica-based nanomedicines.
Hao N; Li L; Tang F
Biomater Sci; 2016 Apr; 4(4):575-91. PubMed ID: 26818852
[TBL] [Abstract][Full Text] [Related]
34. Recent advances in green nanoparticulate systems for drug delivery: efficient delivery and safety concern.
Lam PL; Wong WY; Bian Z; Chui CH; Gambari R
Nanomedicine (Lond); 2017 Feb; 12(4):357-385. PubMed ID: 28078952
[TBL] [Abstract][Full Text] [Related]
35. Controlling the morphology of copolymeric vectors for next generation nanomedicine.
Williams DS; Pijpers IAB; Ridolfo R; van Hest JCM
J Control Release; 2017 Aug; 259():29-39. PubMed ID: 28257992
[TBL] [Abstract][Full Text] [Related]
36. Towards a nanospecific approach for risk assessment.
Dekkers S; Oomen AG; Bleeker EA; Vandebriel RJ; Micheletti C; Cabellos J; Janer G; Fuentes N; Vázquez-Campos S; Borges T; Silva MJ; Prina-Mello A; Movia D; Nesslany F; Ribeiro AR; Leite PE; Groenewold M; Cassee FR; Sips AJ; Dijkzeul A; van Teunenbroek T; Wijnhoven SW
Regul Toxicol Pharmacol; 2016 Oct; 80():46-59. PubMed ID: 27255696
[TBL] [Abstract][Full Text] [Related]
37. Nanoparticles: pharmacological and toxicological significance.
Medina C; Santos-Martinez MJ; Radomski A; Corrigan OI; Radomski MW
Br J Pharmacol; 2007 Mar; 150(5):552-8. PubMed ID: 17245366
[TBL] [Abstract][Full Text] [Related]
38. Biomedical applications and potential health risks of nanomaterials: molecular mechanisms.
Lanone S; Boczkowski J
Curr Mol Med; 2006 Sep; 6(6):651-63. PubMed ID: 17022735
[TBL] [Abstract][Full Text] [Related]
39. Cytokines as biomarkers of nanoparticle immunotoxicity.
Elsabahy M; Wooley KL
Chem Soc Rev; 2013 Jun; 42(12):5552-76. PubMed ID: 23549679
[TBL] [Abstract][Full Text] [Related]
40. Effects of engineered nanoparticles on the innate immune system.
Liu Y; Hardie J; Zhang X; Rotello VM
Semin Immunol; 2017 Dec; 34():25-32. PubMed ID: 28985993
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
